181 related articles for article (PubMed ID: 17513600)
1. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
Yin L; Morishige K; Takahashi T; Hashimoto K; Ogata S; Tsutsumi S; Takata K; Ohta T; Kawagoe J; Takahashi K; Kurachi H
Mol Cancer Ther; 2007 May; 6(5):1517-25. PubMed ID: 17513600
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor.
Hata Y; Miura M; Nakao S; Kawahara S; Kita T; Ishibashi T
Jpn J Ophthalmol; 2008; 52(1):16-23. PubMed ID: 18369695
[TBL] [Abstract][Full Text] [Related]
3. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.
Takata K; Morishige K; Takahashi T; Hashimoto K; Tsutsumi S; Yin L; Ohta T; Kawagoe J; Takahashi K; Kurachi H
Mol Cancer Ther; 2008 Jun; 7(6):1551-61. PubMed ID: 18566226
[TBL] [Abstract][Full Text] [Related]
4. Fasudil inhibits prostate cancer-induced angiogenesis in vitro.
Chen W; Mao K; Hua-Huy T; Bei Y; Liu Z; Dinh-Xuan AT
Oncol Rep; 2014 Dec; 32(6):2795-802. PubMed ID: 25333508
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis.
Kroll J; Epting D; Kern K; Dietz CT; Feng Y; Hammes HP; Wieland T; Augustin HG
Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H893-9. PubMed ID: 19181962
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
7. Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration.
Zhang Z; Ren JH; Li ZY; Nong L; Wu G
Oncol Rep; 2012 May; 27(5):1561-6. PubMed ID: 22344855
[TBL] [Abstract][Full Text] [Related]
8. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
[TBL] [Abstract][Full Text] [Related]
9. Rho kinase inhibition by fasudil suppresses lipopolysaccharide-induced apoptosis of rat pulmonary microvascular endothelial cells via JNK and p38 MAPK pathway.
Liu H; Chen X; Han Y; Li C; Chen P; Su S; Zhang Y; Pan Z
Biomed Pharmacother; 2014 Apr; 68(3):267-75. PubMed ID: 24406296
[TBL] [Abstract][Full Text] [Related]
10. The Rho kinase inhibitor fasudil augments the number of functional endothelial progenitor cells in ex vivo cultures.
O E; Ahn HY; Kim HK; You JC; Shin JC; Joe YA
Int J Mol Med; 2011 Sep; 28(3):357-63. PubMed ID: 21567077
[TBL] [Abstract][Full Text] [Related]
11. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
Ogata S; Morishige K; Sawada K; Hashimoto K; Mabuchi S; Kawase C; Ooyagi C; Sakata M; Kimura T
Int J Gynecol Cancer; 2009 Dec; 19(9):1473-80. PubMed ID: 19955921
[TBL] [Abstract][Full Text] [Related]
12. Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.
Xia Y; Cai XY; Fan JQ; Zhang LL; Ren JH; Chen J; Li ZY; Zhang RG; Zhu F; Wu G
Mol Cancer Ther; 2015 Jul; 14(7):1582-90. PubMed ID: 25934709
[TBL] [Abstract][Full Text] [Related]
13. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
Zhu F; Zhang Z; Wu G; Li Z; Zhang R; Ren J; Nong L
Med Oncol; 2011 Jun; 28(2):565-71. PubMed ID: 20300976
[TBL] [Abstract][Full Text] [Related]
14. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
Ying H; Biroc SL; Li WW; Alicke B; Xuan JA; Pagila R; Ohashi Y; Okada T; Kamata Y; Dinter H
Mol Cancer Ther; 2006 Sep; 5(9):2158-64. PubMed ID: 16985048
[TBL] [Abstract][Full Text] [Related]
15. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
Deng L; Li G; Li R; Liu Q; He Q; Zhang J
Cancer Biol Ther; 2010 Jun; 9(11):875-84. PubMed ID: 20364104
[TBL] [Abstract][Full Text] [Related]
16. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis.
Sulochana KN; Fan H; Jois S; Subramanian V; Sun F; Kini RM; Ge R
J Biol Chem; 2005 Jul; 280(30):27935-48. PubMed ID: 15923192
[TBL] [Abstract][Full Text] [Related]
17. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.
Li H; Peng W; Jian W; Li Y; Li Q; Li W; Xu Y
Cardiovasc Diabetol; 2012 Jun; 11():65. PubMed ID: 22694757
[TBL] [Abstract][Full Text] [Related]
18. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells.
Fukushima M; Nakamuta M; Kohjima M; Kotoh K; Enjoji M; Kobayashi N; Nawata H
Liver Int; 2005 Aug; 25(4):829-38. PubMed ID: 15998434
[TBL] [Abstract][Full Text] [Related]
19. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F
Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase C-mediated contraction by Rho kinase inhibitor fasudil in rabbit aorta.
Shimomura E; Shiraishi M; Iwanaga T; Seto M; Sasaki Y; Ikeda M; Ito K
Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):414-22. PubMed ID: 15459803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
